Evidence map›Paper›PMID 40355804›Full record

ArticleCancer science2025

Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma.

Takuya Shimizu, Takero Shindo, Hanako Ogawa, Kaori Teranaka, Akira Watanabe, Akifumi Takaori-Kondo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takuya ShimizuDepartment of Hematology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takero ShindoDepartment of Hematology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2085-6151
Hanako OgawaCyberomiX, Inc., Kyoto, Japan.
Kaori TeranakaCyberomiX, Inc., Kyoto, Japan.
Akira WatanabeCyberomiX, Inc., Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Funding

Japan Agency for Medical Research and Development JP21ek0510035h0001-0003Japan Society for the Promotion of Science JP19K08812Japan Society for the Promotion of Science JP23K07811Uehara Memorial Foundation Grant-in-aid
6 · The paper itself

Abstract

The clinical and genetic presentation of adult T-cell leukemia/lymphoma (ATLL) ranges from indolent to aggressive, making it difficult to identify common therapeutic targets. Inhibiting EZH1/2 suppresses ATLL through epigenetic modulation; however, the diverse genetic background of ATLL precludes its mode of action from being clearly elucidated. We conducted single-cell RNA sequencing (scRNA-seq) of primary ATLL cells and identified an epigenetic regulative axis. First, flow cytometry showed that the proliferative potential of CADM1

Indexed as

Enhancer of Zeste Homolog 2 ProteinLeukemia-Lymphoma, Adult T-CellMutL Protein Homolog 1YY1 Transcription FactorCell Line, TumorCell ProliferationEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansUp-RegulationEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMLH1 protein, humanMutL Protein Homolog 1YY1 protein, humanYY1 Transcription Factoradult T‐cell leukemia/lymphoma (ATLL)EZH2MLH1single‐cell RNA sequencingYY1

Identifiers

PMID40355804
PMCPMC12317392

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.